Education
About Us
Working with TipRanks
Follow Us
Cabaletta Bio (CABA)
NASDAQ:CABA
CABA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.59 - $19.04
Previous CloseN/A
Volume846.62K
Average Volume (3M)1.06M
Market Cap
$84.07M
Enterprise Value$65.71M
Total Cash (Recent Filing)$33.02M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta3.41
Next Earnings
May 14, 2025EPS Estimate
-0.64Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.15
Shares Outstanding48,877,163
10 Day Avg. Volume768,890
30 Day Avg. Volume1,062,703
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-1.10
P/FCF Ratio0.00
Enterprise Value/Market Cap0.78
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-0.61
Forecast
1Y Price Target
$27.50Price Target Upside1556.63% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
---
Cabaletta Bio News
PremiumCompany Announcements
Cabaletta Bio Unveils Promising Clinical Data in RESET Trials
PremiumCompany Announcements
Cabaletta Bio Advances Clinical Trials with Lonza Partnership
---
Bulls Say, Bears Say
Bulls Say
Clinical Trials ProgressCABA continues to make rapid progress with 26 patients enrolled and 50 sites recruiting across RESET clinical trials.
Regulatory EngagementBoth indications have fast-track designation by the FDA.
Bears Say
Competitive MarketShares are down -88% YTD as worry over CABA-201's safety profile, competition from BiSpecs & allogeneic CAR T programs in I&I, and its cash overhang have negatively impacted shares and sentiment.
Financial ConstraintsThe company only has cash into 1H26, which will weigh on shares and cap upside for the stock.
---
Ownership Overview
5.84%
Insiders
23.93% Mutual Funds
36.94% Other Institutional Investors
24.40% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
CABA FAQ
What was Cabaletta Bio’s price range in the past 12 months?
Cabaletta Bio lowest stock price was $1.59 and its highest was $19.04 in the past 12 months.
What is Cabaletta Bio’s market cap?
Cabaletta Bio’s market cap is $84.07M.
When is Cabaletta Bio’s upcoming earnings report date?
Cabaletta Bio’s upcoming earnings report date is May 14, 2025 which is in 48 days.
How were Cabaletta Bio’s earnings last quarter?
Currently, no data Available
Is Cabaletta Bio overvalued?
According to Wall Street analysts Cabaletta Bio’s price is currently Undervalued.
Does Cabaletta Bio pay dividends?
Cabaletta Bio does not currently pay dividends.
What is Cabaletta Bio’s EPS estimate?
Cabaletta Bio’s EPS estimate is -0.64.
How many shares outstanding does Cabaletta Bio have?
Cabaletta Bio has 48,877,163 shares outstanding.
What happened to Cabaletta Bio’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Cabaletta Bio?
Currently, no hedge funds are holding shares in CABA
---
Cabaletta Bio Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$27.50 (1556.63% Upside)
$27.50 (1556.63% Upside)
Blogger Sentiment
Neutral
CABA Sentiment 50%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 23.6K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.3%
Last 30 Days ▼ 7.1%
Last 30 Days ▼ 7.1%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-90.11%
12-Months-Change
Fundamentals
Return on Equity
-62.16%
Trailing 12-Months
Asset Growth
17.96%
Trailing 12-Months
Company Description
Cabaletta Bio
Cabaletta Bio (CABA) is a biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's proprietary technology platform aims to create precise, targeted therapies that can specifically eliminate disease-causing B cells while preserving healthy immune function. Cabaletta Bio is dedicated to transforming the treatment landscape for autoimmune diseases by offering innovative therapeutic solutions.
---
CABA Stock 12 Month Forecast
Average Price Target
$27.50
▲(1556.63% Upside)
Technical Analysis
MacroGenics
―
Fate Therapeutics
―
Adaptimmune Therapeutics
―
Precision BioSciences
―
Kalaris Therapeutics
―
Best Analysts Covering CABA
1 Year
1 Year Success Rate
10/21 ratings generated profit
1 Year Average Return
+173.71%
reiterated a buy rating last month
Copying Douglas Tsao's trades and holding each position for 1 Year would result in 47.62% of your transactions generating a profit, with an average return of +173.71% per trade.
---